Regenxbio (RGNX) Operating Margin (2016 - 2025)
Regenxbio (RGNX) has 12 years of Operating Margin data on record, last reported at 189.99% in Q4 2025.
- For Q4 2025, Operating Margin rose 5216.0% year-over-year to 189.99%; the TTM value through Dec 2025 reached 94.58%, up 18546.0%, while the annual FY2025 figure was 94.58%, 18546.0% up from the prior year.
- Operating Margin reached 189.99% in Q4 2025 per RGNX's latest filing, down from 176.27% in the prior quarter.
- Across five years, Operating Margin topped out at 670.14% in Q4 2023 and bottomed at 408.8% in Q1 2024.
- Average Operating Margin over 5 years is 180.88%, with a median of 235.12% recorded in 2021.
- Peak YoY movement for Operating Margin: skyrocketed 85445bps in 2023, then tumbled -91229bps in 2024.
- A 5-year view of Operating Margin shows it stood at 78.66% in 2021, then plummeted by -334bps to 184.31% in 2022, then soared by 464bps to 670.14% in 2023, then crashed by -136bps to 242.14% in 2024, then grew by 22bps to 189.99% in 2025.
- Per Business Quant database, its latest 3 readings for Operating Margin were 189.99% in Q4 2025, 176.27% in Q3 2025, and 296.26% in Q2 2025.